{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269535","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.362523+00:00","generated_at":"2026-05-16T23:52:25.470548+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AVITA Medical Q3 revenue falls 13% YoY to $17.1M; lowers FY2025 revenue guidance to $70-74M","bullets":["Net loss improved to $13.2M ($0.46 loss per share) from $16.2M in Q3 2024; cash use cut to $6.2M.","Full-year 2025 revenue guidance lowered to $70-74M from prior $76-81M, citing MAC reimbursement headwinds.","Sixth amendment to OrbiMed credit agreement adds $500K to principal, resets Q4 2025 revenue covenant to $70M.","RECELL GO received CE Mark under EU MDR; launch to begin in Germany, Italy, and UK.","Operating expenses down 24% YoY to $23.0M as part of cost discipline; cash $23.3M at Sept 30."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269535","json":"https://secwatch.observer/filing/0001193125-25-269535.json","markdown":"https://secwatch.observer/filing/0001193125-25-269535.md","text":"https://secwatch.observer/filing/0001193125-25-269535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000119312525269535/0001193125-25-269535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000119312525269535/rcel-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:52:25.470548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}